Bayer's Stroke Medication Achieves Trial Objectives; Analyst Anticipates Favorable Data from Bristol Myers' Milvexian Following Unsuccessful Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Source: Benzinga
Bayer's Phase 3 Study Results: Bayer AG announced positive topline results from the Phase 3 OCEANIC-STROKE study for its oral FXIa inhibitor asundexian, which significantly reduced the risk of ischemic stroke without increasing major bleeding risks compared to placebo.
Impact on Bristol-Myers Squibb: The positive results for asundexian are seen as beneficial for Bristol-Myers Squibb's milvexian program, especially after the recent halt of the LIBREXIA-ACS trial due to lack of efficacy.
Dosing Concerns: Analysts are questioning whether the dosing levels of milvexian being tested are optimal, particularly in light of Bayer's previous findings that indicated insufficient dosing of asundexian in a different study.
Market Reaction: Following the news, Bristol-Myers Squibb's stock rose by 4.57%, reflecting investor optimism regarding the implications of Bayer's trial results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 55.920
Low
37.00
Averages
55.86
High
68.00
Current: 55.920
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Dividend Stocks Worth Investing In
- Bristol Myers Squibb's Growth Potential: Bristol Myers Squibb's Q1 revenue rose 3% year-over-year to $11.5 billion, with new drug sales increasing 12% to $6.2 billion, indicating a strong recovery in its oncology portfolio that could further enhance sales growth in the future.
- Merck's Product Diversification: Despite competitive pressures, Merck's newer products have an annual revenue exceeding $1 billion, with the pulmonary arterial hypertension drug Winrevair generating $525 million in Q1, an impressive 88% year-over-year increase, showcasing the company's strong performance in new markets.
- Medtronic's Strategic Restructuring: Medtronic announced the spin-off of its diabetes care division into a standalone public company to enhance overall operational efficiency, while its new Pulse Field Ablation devices are positively impacting revenue growth in recent quarters.
- Attractive Dividend Yields: All three companies offer attractive dividend yields, with Bristol Myers at 4.4%, Merck at 3%, and Medtronic at 3.6%, all of which have significantly increased their dividends over the past decade, demonstrating a strong commitment to shareholder returns.
See More
Three Healthcare Stocks with Dividend Growth Potential
- Bristol Myers' Recovery: Bristol Myers Squibb's Q1 revenue rose 3% year-over-year to $11.5 billion, driven by new drug approvals and sales growth, which are expected to further enhance sales and market competitiveness in the coming years.
- Merck's Diversification Strategy: Merck's new Keytruda Qlex has been approved, likely extending patent protection, while new products like Winrevair saw an 88% revenue increase in Q1, demonstrating the company's ongoing competitiveness in the cancer drug market.
- Medtronic's Transformation: Medtronic announced the spin-off of its diabetes care division into a standalone company and launched new products like the Hugo system, which are expected to drive revenue growth and strengthen its position in the medical device market.
- Dividend Appeal: All three companies offer attractive dividend yields, with Bristol Myers at 4.4%, Merck at 3%, and Medtronic at 3.6%, showcasing their stability and appeal for long-term investors.
See More
Trump Announces US-Iran Deal, Market Rallies
- Market Rally: Following Trump's announcement of a US-Iran peace deal, the S&P 500 rose by 1.85%, marking its best performance since April 8, indicating a positive market reaction to reduced geopolitical risks.
- Tech Sector Surge: The Nasdaq jumped over 3%, achieving its best session since March 31, reflecting renewed investor confidence in tech stocks, which may drive future investment inflows.
- Pharma Stock Pressure: Pharmaceutical stocks face downward pressure after the Centers for Medicare and Medicaid Services proposed new drug price negotiations, with analysts warning of potential risks for companies like Johnson & Johnson and Bristol Myers, impacting their short-term performance.
- Salesforce Acquisition: Salesforce announced its acquisition of customer service platform Fin for $3.6 billion, expected to close in Q4 of fiscal year 2027, aimed at enhancing its AI customer service capabilities, although its stock failed to maintain gains during the market rally, highlighting uncertainty about AI's long-term impact.
See More
Analysis of SCHD ETF's 52-Week Price Fluctuations
- Price Range Analysis: SCHD ETF's 52-week low is $26.16 per share, with a high of $32.915, and the latest trade at $32.77 indicates stability near its peak, potentially attracting investor interest in its price movements.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and identify potential buy or sell opportunities.
- ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling, thus affecting individual stock performance.
See More
Bristol Myers Squibb Offers 4.5% Yield Amid Patent Challenges
- Dividend Appeal: Bristol Myers Squibb offers a 4.5% yield, significantly higher than the S&P 500's 1% and the drug sector's 1.6%, indicating strong investor attraction, although the high yield raises concerns about dividend safety.
- Strong Financial Position: The company holds an investment-grade credit rating with a current debt-to-equity ratio of 2.2, down from 3.0 at the end of 2024, and an interest coverage ratio of 6.3, suggesting ample financial flexibility to meet debt obligations, thereby enhancing dividend safety.
- Patent Expiration Risks: Bristol Myers Squibb faces patent expirations for key drugs like Revlimid, Pomalyst, and Eliquis, which will materially pressure revenues and profits over the next few years; while the company is developing new drugs to offset revenue losses, timing mismatches may lead to an increased payout ratio.
- Investor Confidence: Despite uncertainties, the company's long history of success, reasonable payout ratio, and strong financial standing provide most investors with confidence that the dividend will remain intact amid the patent expiration challenges.
See More
Analysis of Bristol Myers Squibb's Dividend Safety
- Dividend Yield Advantage: Bristol Myers Squibb offers a 4.5% dividend yield, significantly higher than the S&P 500's 1% and the drug sector's 1.6%, making it attractive to investors, although the high yield raises concerns about dividend safety.
- Financial Strength: The company holds an investment-grade credit rating, with a current debt-to-equity ratio of 2.2, down from 3 at the end of 2024, and an interest coverage ratio of 6.3, indicating ample leeway to meet debt obligations and enhancing its ability to sustain dividends.
- Patent Expiration Risks: Bristol Myers Squibb faces patent expirations for key drugs like Revlimid, Pomalyst, and Eliquis, which will materially pressure revenues and profits over the next few years, although the company is working on new drug development to offset lost revenue.
- Payout Ratio Analysis: The current dividend payout ratio is around 72%, which is somewhat high but not unreasonable, suggesting there is some buffer before a potential cut, and investors should monitor how the company navigates the challenges posed by patent expirations.
See More
Three Dividend Stocks Worth Investing In
- Bristol Myers Squibb's Growth Potential: Bristol Myers Squibb's Q1 revenue rose 3% year-over-year to $11.5 billion, with new drug sales increasing 12% to $6.2 billion, indicating a strong recovery in its oncology portfolio that could further enhance sales growth in the future.
- Merck's Product Diversification: Despite competitive pressures, Merck's newer products have an annual revenue exceeding $1 billion, with the pulmonary arterial hypertension drug Winrevair generating $525 million in Q1, an impressive 88% year-over-year increase, showcasing the company's strong performance in new markets.
- Medtronic's Strategic Restructuring: Medtronic announced the spin-off of its diabetes care division into a standalone public company to enhance overall operational efficiency, while its new Pulse Field Ablation devices are positively impacting revenue growth in recent quarters.
- Attractive Dividend Yields: All three companies offer attractive dividend yields, with Bristol Myers at 4.4%, Merck at 3%, and Medtronic at 3.6%, all of which have significantly increased their dividends over the past decade, demonstrating a strong commitment to shareholder returns.
See More
Three Healthcare Stocks with Dividend Growth Potential
- Bristol Myers' Recovery: Bristol Myers Squibb's Q1 revenue rose 3% year-over-year to $11.5 billion, driven by new drug approvals and sales growth, which are expected to further enhance sales and market competitiveness in the coming years.
- Merck's Diversification Strategy: Merck's new Keytruda Qlex has been approved, likely extending patent protection, while new products like Winrevair saw an 88% revenue increase in Q1, demonstrating the company's ongoing competitiveness in the cancer drug market.
- Medtronic's Transformation: Medtronic announced the spin-off of its diabetes care division into a standalone company and launched new products like the Hugo system, which are expected to drive revenue growth and strengthen its position in the medical device market.
- Dividend Appeal: All three companies offer attractive dividend yields, with Bristol Myers at 4.4%, Merck at 3%, and Medtronic at 3.6%, showcasing their stability and appeal for long-term investors.
See More
Trump Announces US-Iran Deal, Market Rallies
- Market Rally: Following Trump's announcement of a US-Iran peace deal, the S&P 500 rose by 1.85%, marking its best performance since April 8, indicating a positive market reaction to reduced geopolitical risks.
- Tech Sector Surge: The Nasdaq jumped over 3%, achieving its best session since March 31, reflecting renewed investor confidence in tech stocks, which may drive future investment inflows.
- Pharma Stock Pressure: Pharmaceutical stocks face downward pressure after the Centers for Medicare and Medicaid Services proposed new drug price negotiations, with analysts warning of potential risks for companies like Johnson & Johnson and Bristol Myers, impacting their short-term performance.
- Salesforce Acquisition: Salesforce announced its acquisition of customer service platform Fin for $3.6 billion, expected to close in Q4 of fiscal year 2027, aimed at enhancing its AI customer service capabilities, although its stock failed to maintain gains during the market rally, highlighting uncertainty about AI's long-term impact.
See More
Analysis of SCHD ETF's 52-Week Price Fluctuations
- Price Range Analysis: SCHD ETF's 52-week low is $26.16 per share, with a high of $32.915, and the latest trade at $32.77 indicates stability near its peak, potentially attracting investor interest in its price movements.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and identify potential buy or sell opportunities.
- ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling, thus affecting individual stock performance.
See More
Bristol Myers Squibb Offers 4.5% Yield Amid Patent Challenges
- Dividend Appeal: Bristol Myers Squibb offers a 4.5% yield, significantly higher than the S&P 500's 1% and the drug sector's 1.6%, indicating strong investor attraction, although the high yield raises concerns about dividend safety.
- Strong Financial Position: The company holds an investment-grade credit rating with a current debt-to-equity ratio of 2.2, down from 3.0 at the end of 2024, and an interest coverage ratio of 6.3, suggesting ample financial flexibility to meet debt obligations, thereby enhancing dividend safety.
- Patent Expiration Risks: Bristol Myers Squibb faces patent expirations for key drugs like Revlimid, Pomalyst, and Eliquis, which will materially pressure revenues and profits over the next few years; while the company is developing new drugs to offset revenue losses, timing mismatches may lead to an increased payout ratio.
- Investor Confidence: Despite uncertainties, the company's long history of success, reasonable payout ratio, and strong financial standing provide most investors with confidence that the dividend will remain intact amid the patent expiration challenges.
See More
Analysis of Bristol Myers Squibb's Dividend Safety
- Dividend Yield Advantage: Bristol Myers Squibb offers a 4.5% dividend yield, significantly higher than the S&P 500's 1% and the drug sector's 1.6%, making it attractive to investors, although the high yield raises concerns about dividend safety.
- Financial Strength: The company holds an investment-grade credit rating, with a current debt-to-equity ratio of 2.2, down from 3 at the end of 2024, and an interest coverage ratio of 6.3, indicating ample leeway to meet debt obligations and enhancing its ability to sustain dividends.
- Patent Expiration Risks: Bristol Myers Squibb faces patent expirations for key drugs like Revlimid, Pomalyst, and Eliquis, which will materially pressure revenues and profits over the next few years, although the company is working on new drug development to offset lost revenue.
- Payout Ratio Analysis: The current dividend payout ratio is around 72%, which is somewhat high but not unreasonable, suggesting there is some buffer before a potential cut, and investors should monitor how the company navigates the challenges posed by patent expirations.
See More
